Needham lowered the firm’s price target on TScan Therapeutics (TCRX) to $6 from $9 and keeps a Buy rating on the shares. TScan is consolidating its efforts on lead heme program TSC-101, with an ASH abstract suggesting some loss of activity with TSC-101 compared to data from last year, the analyst tells investors in a research note. Despite these and other recent challenges, the firm continues to view TSC-101 as an important potential solution for rapid relapse in patients receiving transplant.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
- TScan Therapeutics Shifts Focus to Hematologic Malignancies
- TScan Therapeutics to reduce workforce by 30%
- TScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid Tumors
- TScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies